AAL:LSE

Anglo American plc

Data as of 2026-03-10 - not real-time

£3,127.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Anglo American trades at 3,127 GBp, sitting below its 20‑day SMA (3,560) but above the 200‑day SMA (2,731), indicating a long‑term uptrend yet short‑term weakness. The 14‑day RSI of 34 signals oversold conditions, while a bearish MACD histogram of –69 supports a near‑term downside bias. Volume is increasing and the price holds just above the identified support at 3,002, with resistance near 3,877. Volatility is elevated at 45% over the past month and beta under 1 points to modest market sensitivity. The DCF model suggests a fair value around 9,407 GBp, implying a potential upside of over 200% versus the current level, though the forward P/E of 18.8 is modest.
Fundamentals are mixed – a 17.5% revenue growth year‑over‑year is offset by a negative profit margin and a trailing EPS of –0.79, yet forward EPS is projected at 1.66, indicating a turnaround. The company carries high leverage (debt‑to‑equity 65.5) and a dividend yield of 0.54% with an unsustainable payout ratio above 500%, reflected in the recent dividend cut. Material news highlights a 10% drop in copper output, a cut to 2026 guidance, and a downgrade by JP Morgan, but also the advancing Anglo‑Tech merger with Teck, which could unlock significant synergies. Overall, the stock appears heavily discounted relative to intrinsic models but faces short‑term execution and sector headwinds.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD and price below 20‑day SMA
  • Recent dividend cut and JP Morgan downgrade
  • Support level near 3,002 limiting downside

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Progress on Anglo‑Tech merger delivering synergies
  • Forward EPS upside and modest forward P/E
  • Significant intrinsic value gap per DCF

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Long‑term demand for copper and iron ore
  • Potential de‑leveraging and cash‑flow improvement
  • Strategic asset sales and portfolio optimisation

Key Metrics & Analysis

Financial Health

Revenue Growth17.50%
Profit Margin-20.17%
P/E Ratio18.8
ROE-2.67%
ROA4.11%
Debt/Equity65.51
P/B Ratio247.9
Op. Cash Flow£5.5B
Free Cash Flow£-591625024

Technical Analysis

TrendBullish
RSI34.5
Support£3,002.00
Resistance£3,877.00
MA 20£3,559.50
MA 50£3,412.08
MA 200£2,731.14
MACDBearish
VolumeIncreasing
Fear & Greed Index75.89

Valuation

Fair Value£9,406.96
Target Price£3,475.23
Upside/Downside11.14%
GradeUndervalued
TypeBlend
Dividend Yield0.54%

Risk Assessment

Beta0.64
Volatility45.75%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.